Current status and future directions in lipid management: Emphasizing low-density lipoproteins, high-density lipoproteins, and triglycerides as targets for therapy

Vascular Health and Risk Management

Volumn 6, Issue 1, 2010, Pages 73-85

  Lin, Yun ^a   Mousa, Shaymaa S ^a   Elshourbagy, Nabil ^a   Mousa, Shaker A ^a  

^a ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

Author keywords

Atherosclerosis; Cholesterol; Coronary heart diseases; Fibric acid; HDL C; LDL C; Lipid; Nicotinic acid; Statin; Triglycerides

Indexed keywords

AMLODIPINE PLUS ATORVASTATIN; ANABOLIC AGENT; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BEZAFIBRATE; BILE ACID SEQUESTRANT; COLESEVELAM; COLESTIPOL; COLESTYRAMINE; CORTICOSTEROID; ESTROGEN; EZETIMIBE; EZETIMIBE PLUS SIMVASTATIN; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; GEMFIBROZIL; GESTAGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISOTRETINOIN; LOVASTATIN PLUS NICOTINIC ACID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NICOTINIC ACID; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL; UNINDEXED DRUG;

ACUTE HEART INFARCTION; ANTICOAGULATION; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL METABOLISM; CLINICAL TRIAL; CREATINE KINASE BLOOD LEVEL; DIARRHEA; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG TARGETING; DRUG WITHDRAWAL; DYSLIPIDEMIA; FLATULENCE; HEART INFARCTION; HEARTBURN; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; HYPOCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; LIPID TRANSPORT; LIPOPROTEIN METABOLISM; MORBIDITY; MORTALITY; MUSCLE FATIGUE; MUSCLE WEAKNESS; MYALGIA; MYOPATHY; MYOSITIS; NAUSEA; OVERALL SURVIVAL; PATIENT COMPLIANCE; PLEIOTROPY; PRACTICE GUIDELINE; PROTEIN SYNTHESIS INHIBITION; REVIEW; RHABDOMYOLYSIS; SIDE EFFECT; SYSTEMATIC REVIEW; THROMBOCYTE AGGREGATION INHIBITION; TREATMENT OUTCOME; VOMITING;

CORONARY DISEASE; DYSLIPIDEMIAS; FEMALE; FORECASTING; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPOPROTEINS, HDL; LIPOPROTEINS, LDL; MALE; SEX FACTORS; TRIGLYCERIDES;

EID: 77950801839     PISSN: 11766344     EISSN: 11782048     Source Type: Journal    
DOI: None     Document Type: Review

References (56)

1. Disease Statistics. 2007 NHLBI Fact Book, Chapter 4. Available at: http://www.nhlbi.nih.gov/about/factbook/chapter4.htm. Accessed 27 May, 2008.
2. Framingham Heart Study: Design, Rationale, and Objectives. September 20; Available at: http://www.nhlbi.nih.gov/about/framingham/design.htm. Accessed May 27, 2008.
3. Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Bethesda: US Department of Health and Human Services, Public Health Service, National Institutes of Health, National Heart, Lung and Blood Institute; 2001.
4. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110(2):227-239.
5. Fletcher B, Berra K, Ades P, et al. Managing abnormal blood lipids: a collaborative approach. Circulation. 2005;112(20):3184-3209.
6. VA/DoD clinical practice guideline for the management of dyslipidemia. Available at: http://www.guideline.gov.
7. Lipid management in adults. Available at: http://www.guideline.gov.
8. McCrindle BW, Urbina EM, Dennison BA, et al. Drug therapy of high-risk lipid abnormalities in children and adolescents: a scientific statement from the American Heart Association Atherosclerosis, Hyper-tension, and Obesity in Youth Committee, Council of Cardiovascular Disease in the Young, with the Council on Cardiovascular Nursing. Circulation. 2007;115(14):1948-1967.
9. Talbert RL. Hyperlipidemia. In: DiPiro JT, Talbert RL, Yee GC, Matzko GR, G. Wells B, Posey LM, editors. Pharmacotherapy: A Pathophysiologic Approach. 6th ed. New York: McGraw-Hill; Medical Publishing Division; 2005.
10. Dietschy JM. Dietary fatty acids and the regulation of plasma low density lipoprotein cholesterol concentrations. J Nutr. 1998; 128(2 Suppl):444S-448S.
11. Mahley RW, Bersot TP. Chapter 35: Drug therapy for hypercholesterolemia and dyslipidemia. In: Brunton LL, editors. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 11th edition. New York: McGraw-Hill Companies, Inc.; 2006.
12. Malloy MJ, Kane JP. Agents used in hyperlipidemia. In: Katzung BG. Basic and Clinical Pharmacology. 9th ed. New York: The McGraw-Hill Companies, Inc.; 2004:561-575.
13. Nofer JR, Kehrel B, Fobker M, Levkau B, Assmann G, von Eckardstein A. HDL and arteriosclerosis: beyond reverse cholesterol transport. Atherosclerosis. 2002;161(1):1-16.
14. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998;279(20):1615-1622.
15. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med. 1998;339(19):1349-1357.
16. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 1996;335(14):1001-1009.
17. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995;333(20):1301-1307.
18. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344(8934):1383-1389.
19. Pedersen TR, Olsson AG, Faergeman O, et al. Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S). Circulation. 1998;97(15):1453-1460.
20. The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA. 1984;251(3):365-374.
21. Manninen V, Elo MO, Frick MH, et al. Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. JAMA. 1988;260(5):641-651.
22. Bruckert E, Baccara-Dinet M, McCoy F, Chapman J. High prevalence of low HDL-cholesterol in a pan-European survey of 8545 dyslipidaemic patients. Curr Med Res Op. 2005;21(12):1927-1934.
23. Aguilar-Salinas CA, Olaiz G, Valles V, et al. High prevalence of low HDL cholesterol concentrations and mixed hyperlipidemia in a Mexican nationwide survey. J Lipid Res. 2001;42(8):1298-1307.
24. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97(18):1837-1847.
25. Mineo C, Deguchi H, Griffin JH, Shaul PW. Endothelial and antithrombotic actions of HDL. Circ Res. 2006;98(11):1352-1364.
26. Barter PJ, Nicholls S, Rye KA, Anantharamaiah GM, Navab M, Fogelman AM. Antiinflammatory properties of HDL. Circ Res. 2004;95(8):764-772.
27. Goldenberg I, Goldbourt U, Boyko V, Behar S, Reicher-Reiss H. Relation between on-treatment increments in serum high-density lipoprotein cholesterol levels and cardiac mortality in patients with coronary heart disease (from the Bezafibrate Infarction Prevention trial). Am J Cardiol. 2006;97(4):466-471.
28. Robins SJ, Collins D, Wittes JT, et al. Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. JAMA. 2001;285(12):1585-1591.
29. Dean BB, Borenstein JE, Henning JM, Knight K, Merz CN. Can change in high-density lipoprotein cholesterol levels reduce cardiovascular risk? Am Heart J. 2004;147(6):966-976.
30. Sviridov D, Mukhamedova N, Remaley AT, Chin-Dusting J, Nestel P. Antiatherogenic functionality of high density lipoprotein: how much versus how good. J Atheroscler Thromb. 2008;15(2):52-62.
31. Assmann G, Schulte H, Funke H, von Eckardstein A. The emergence of triglycerides as a significant independent risk factor in coronary artery disease. Eur Heart J. 1998;19 (Suppl M): M8-M14.
32. Austin MA, Hokanson JE, Edwards KL. Hypertriglyceridemia as a cardiovascular risk factor. Am J Cardiol. 1998;81(4A):7B-12B.
33. Assmann G, Cullen P, Schulte H. The Munster Heart Study (PROCAM). Results of follow-up at 8 years. Eur Heart J. 1998;19 (Suppl A): A2-A11.
34. Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk. 1996;3(2):213-219.
35. Tenkanen L, Pietila K, Manninen V, Manttari M. The triglyceride issue revisited. Findings from the Helsinki Heart Study. Arch Int Med. 1994;154(23):2714-2720.
36. Avins AL, Neuhaus JM. Do triglycerides provide meaningful information about heart disease risk? Arch Int Med. 2000;160(13): 1937-1944.
37. Pravastatin sodium. Available at: http://www.thomsonhc.com. Accessed June 16, 2008.
38. Atorvastatin calcium. Available at: http://www.thomsonhc.com. Accessed June 16, 2008.
39. Simvastatin. Available at: http://www.thomsonhc.com. Accessed June 16, 2008.
40. Lovastatin. Available at: http://www.thomsonhc.com. Accessed June 16, 2008.
41. Fluvastatin sodium. Available at: http://www.thomsonhc.com. Accessed June 16, 2008.
42. Rosuvastatin calcium. Available at: http://www.thomsonhc.com. Accessed June 16, 2008.
43. Pasternak RC, Smith SC Jr. Bairey-Merz CN, Grundy SM, Cleeman JI, Lenfant C. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. J Am Coll Cardiol. 2002;40(3):567-572.
44. Cholestyramine. Available at: http://www.thomsonhc.com. Accessed June 16, 2008.
45. Colestipol hydrochloride. Available at: http://www.thomsonhc.com. Accessed June 16, 2008.
46. Colesevelam hydrochloride. Available at: http://www.thomsonhc.com. Accessed June 16, 2008.
47. Niacin. Available at: http://www.thomsonhc.com. Accessed June 16, 2008.
48. Kersten S, Desvergne B, Wahli W. Roles of PPARs in health and disease. Nature. 2000;405(6785):421-424.
49. Fenofibrate. Available at: http://www.thomsonhc.com. Accessed June 16, 2008.
50. Gemfibrozil. Available at: http://www.thomsonhc.com. Accessed June 16, 2008.
51. Zetia (ezetimibe) tablet. Feb 2008; Available at: http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=7380. Accessed June 16, 2008.
52. Ezetimibe. Available at: http://www.thomsonhc.com. Accessed June 16, 2008.
53. Hausenloy DJ, Yellon DM. Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels. Heart. 2008;94(6): 706-714.
54. Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med. 1999;341(6):410-418.
55. Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study: primaryprevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med. 1987;317(20):1237-1245.
56. Richmond C. Cholesterol management. The Rx Consultant. 2006;15(2).